Traders sold shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) on strength during trading hours on Monday. $58.69 million flowed into the stock on the tick-up and $77.59 million flowed out of the stock on the tick-down, for a money net flow of $18.90 million out of the stock. Of all equities tracked, Alnylam Pharmaceuticals had the 0th highest net out-flow for the day. Alnylam Pharmaceuticals traded up $0.71 for the day and closed at $66.20

A number of brokerages have commented on ALNY. Cowen and Company reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, April 17th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Credit Suisse Group AG reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, April 14th. Finally, Jefferies Group reissued a “buy” rating and issued a $119.00 price objective (down previously from $122.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, May 4th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $117.82.

The firm’s market cap is $5.66 billion. The company has a 50 day moving average price of $61.42 and a 200 day moving average price of $63.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.16. The company had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $7.79 million. The business’s revenue for the quarter was down 60.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.62) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals Inc. will post ($4.94) EPS for the current fiscal year.

In related news, CEO John Maraganore sold 30,151 shares of the stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Other large investors have added to or reduced their stakes in the company. Mutual of America Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 21,637 shares of the biopharmaceutical company’s stock worth $2,037,000 after buying an additional 87 shares during the period. Gulf International Bank UK Ltd raised its stake in Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock worth $2,175,000 after buying an additional 220 shares during the period. Advisors Asset Management Inc. raised its stake in Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 64,827 shares of the biopharmaceutical company’s stock worth $6,103,000 after buying an additional 226 shares during the period. TD Asset Management Inc. raised its stake in Alnylam Pharmaceuticals by 11.5% in the fourth quarter. TD Asset Management Inc. now owns 21,300 shares of the biopharmaceutical company’s stock worth $2,005,000 after buying an additional 2,200 shares during the period. Finally, Jennison Associates LLC raised its stake in Alnylam Pharmaceuticals by 0.5% in the fourth quarter. Jennison Associates LLC now owns 1,489,541 shares of the biopharmaceutical company’s stock worth $140,225,000 after buying an additional 7,296 shares during the period.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.